8 February 2018 EMA/88406/2018 Human Medicines Evaluation Division

List of nationally authorised medicinal products

Active substance: benserazide / levodopa

Procedure no.: PSUSA/00000330/201706

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5525 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.

Product Name (in

MRP/DCP

MAH of product in the

Member State where

authorisation country)

Authorisation

member state

product is authorised

6366 13503 731657 890032 812707 731877 792435

ROCHE ROCHE ROCHE ROCHE ROCHE ROCHE ROCHE

DK DK IS IS IS IS IS

not available

023142019

ROCHE S.P.A.

IT

not available

023142045

ROCHE S.P.A.

IT

not available

023142058

ROCHE S.P.A.

IT

not available

1-21773

ROCHE AUSTRIA GMBH

AT

not available

1-22672

ROCHE AUSTRIA GMBH

AT

not available

00-0724

ROCHE LATVIJA SIA

LV

not available

9882

ROCHE OY

FI

not available

184197

ROCHE EESTI OÜ

EE

not available

00-0723

ROCHE LATVIJA SIA

LV

not available

LT/1/94/0936/002

UAB "ROCHE LIETUVA"

LT

not available

PL 00031/0221

ROCHE PRODUCTS LTD

UK

not available

H/96/00958/001

ROCHE FARMACEVTSKA DRUŽBA D.O.O.

SI

National Authorisation Number

number Madopar "125" Madopar "125" Madopar “125“ hörð hylki Madopar “125“ töflur Madopar “250“ töflur Madopar „250“ hörð hylki Madopar „62,5“ hörð hylki Madopar 100 mg + 25 mg capsule rigide Madopar 100 mg + 25 mg capsule rigide a rilascio prolungato Madopar 100 mg + 25 mg compresse dispersibili Madopar 100 mg/25 mg - lösliche Tabletten Madopar 100 mg/25 mg - Tabletten Madopar 100 mg/25 mg cietās kapsulas Madopar 100 mg/25 mg depotkapslar Madopar 100 mg/25 mg dispergeeruvad tabletid Madopar 100 mg/25 mg disperģējamās tabletes Madopar 100 mg/25 mg disperguojamosios tabletės Madopar 100 mg/25 mg Dispersible Tablets Madopar 100 mg/25 mg disperzibilne tablete

not not not not not not not

available available available available available available available

List of nationally authorised medicinal products EMA/88406/2018

A/S A/S A/S A/S A/S A/S A/S

Page 2/12

Product Name (in

MRP/DCP

authorisation country)

Authorisation

National Authorisation Number

MAH of product in the

Member State where

member state

product is authorised HU

number Madopar 100 mg/25 mg diszpergálódó tabletta Madopar 100 mg/25 mg Hard Capsules Madopar 100 mg/25 mg Hard Capsules Madopar 100 mg/25 mg kietosios kapsulės Madopar 100 mg/25 mg kõvakapslid Madopar 100 mg/25 mg retard kemény kapszula Madopar 100 mg/25 mg tablete Madopar 100 mg/25 mg tabletter Madopar 100mg/25mg Dispersible Tablets Madopar 12,5/50 kapsler, harde Madopar 125 mg, 100 mg + 25 mg, kapsułki Madopar 125 mg, 100 mg + 25 mg, tabletki do sporządzania zawiesiny doustnej Madopar 125 mg, dispergeerbare tabletten Madopar 125 mg, tabletten Madopar 125 tablete Madopar 200 mg + 50 mg compresse divisibili

not available

OGYI-T-1157/02

not available

MA060/00603

ROCHE (MAGYARORSZÁG) KFT ROCHE PRODUCTS LTD

not available

PL 00031/0073

ROCHE PRODUCTS LTD

UK

not available

LT/1/94/0936/003

UAB "ROCHE LIETUVA"

LT

not available

403902

ROCHE EESTI OÜ

EE

not available

OGYI-T-1157/03

HU

not available

H/96/00958/002

not available

9672

ROCHE (MAGYARORSZÁG) KFT ROCHE FARMACEVTSKA DRUŽBA D.O.O. ROCHE OY

not available

PA 50/43/6

ROCHE PRODUCTS LTD

IE

not available

6694

F. HOFFMANN-LA ROCHE AG

NO

not available

R/0950

ROCHE POLSKA SP.O.O.

PL

not available

7487

ROCHE POLSKA SP.O.O.

PL

not available

RVG 19428

ROCHE NEDERLAND B.V.

NL

not available

RVG 12059

ROCHE NEDERLAND B.V.

NL

not available not available

HR-H-771762650 023142033

ROCHE D.O.O. ROCHE S.P.A.

HR IT

List of nationally authorised medicinal products EMA/88406/2018

MT

SI FI

Page 3/12

Product Name (in

MRP/DCP

authorisation country)

Authorisation

National Authorisation Number

MAH of product in the

Member State where

member state

product is authorised PT

number Madopar 200 mg + 50 mg comprimidos Madopar 200 mg + 50 mg comprimidos Madopar 200 mg/50 mg - Tabletten Madopar 200 mg/50 mg comprimate Madopar 200 mg/50 mg Hard Capsules Madopar 200 mg/50 mg Hard Capsules Madopar 200 mg/50 mg tablete Madopar 200 mg/50 mg tabletes Madopar 200 mg/50 mg tabletės Madopar 200 mg/50 mg tabletid Madopar 200 mg/50 mg tabletta Madopar 200 mg/50 mg tabletter Madopar 200mg/50mg Hard Capsules Madopar 25/100 kapsler, harde Madopar 250 kapsler, hårde Madopar 250 mg, 200 mg + 50 mg, tabletki Madopar 250 mg, tabletten

not available

8557926

not available

8557900

not available

17.235

ROCHE FARMACÊUTICA QUÍMICA, LDA. ROCHE FARMACÊUTICA QUÍMICA, LDA. ROCHE AUSTRIA GMBH

not available

8133/2006/01

ROCHE ROMANIA SRL

RO

not available

MA060/00604

ROCHE PRODUCTS LTD

MT

not available

PL 00031/0074

ROCHE PRODUCTS LTD

UK

not available

H/96/00958/003

SI

not available

96-0643

ROCHE FARMACEVTSKA DRUŽBA D.O.O. ROCHE LATVIJA SIA

not available

LT/1/94/0936/001

UAB "ROCHE LIETUVA"

LT

not available

046594

ROCHE EESTI OÜ

EE

not available

OGYI-T-1157/01

HU

not available

8611

ROCHE (MAGYARORSZÁG) KFT ROCHE OY

not available

PA 50/43/2

ROCHE PRODUCTS LTD

IE

not available

5967

F. HOFFMANN-LA ROCHE AG

NO

not available

6367

ROCHE A/S

DK

not available

R/0951

ROCHE POLSKA SP.O.O.

PL

not available

RVG 11605

ROCHE NEDERLAND B.V.

NL

List of nationally authorised medicinal products EMA/88406/2018

PT AT

LV

FI

Page 4/12

Product Name (in

MRP/DCP

authorisation country)

Authorisation

National Authorisation Number

MAH of product in the

Member State where

member state

product is authorised

number Madopar 250 tablety Madopar 250, tabletter Madopar 50 mg/12,5 mg - Kapseln Madopar 50 mg/12.5 mg Dispersible Tablets Madopar 50 mg/12.5 mg Hard Capsules Madopar 50 mg/12.5 mg Hard Capsules Madopar 50mg/12.5mg Dispersible Tablets Madopar 62,5 kapsler, hårde Madopar 62,5 mg, 50 mg + 12,5 mg, kapsułki Madopar 62,5 mg, 50 mg + 12,5 mg, tabletki do sporządzania zawiesiny doustnej Madopar 62,5 mg, capsules Madopar 62,5 rozpustné tablety Madopar CR 100 mg/25 mg - Kapseln Madopar CR 100 mg/25 mg Prolonged Release Hard Capsules Madopar CR 100 mg/25 mg Prolonged Release Hard Capsules Madopar DEPOT 100 mg/25 mg hörð forðahylki

not available not available not available

27/391/01-C 11363 16.549

ROCHE S. R. O. ROCHE A/S ROCHE AUSTRIA GMBH

CZ DK AT

not available

PL 00031/0220

ROCHE PRODUCTS LTD

UK

not available

MA060/00602

ROCHE PRODUCTS LTD

MT

not available

PL 00031/0125

ROCHE PRODUCTS LTD

UK

not available

PA 50/43/5

ROCHE PRODUCTS LTD

IE

not available

9821

ROCHE A/S

DK

not available

R/0949

ROCHE POLSKA SP.O.O.

PL

not available

7486

ROCHE POLSKA SP.O.O.

PL

not available

RVG 08475

ROCHE NEDERLAND B.V.

NL

not available

27/029/04-C

ROCHE S. R. O.

CZ

not available

1-19177

ROCHE AUSTRIA GMBH

AT

not available

MA060/00601

ROCHE PRODUCTS LTD

MT

not available

PL 00031/0227

ROCHE PRODUCTS LTD

UK

not available

870211

ROCHE A/S

IS

List of nationally authorised medicinal products EMA/88406/2018

Page 5/12

Product Name (in

MRP/DCP

authorisation country)

Authorisation

National Authorisation Number

MAH of product in the

Member State where

member state

product is authorised

number Madopar Depot 25/100 depotkapsler Madopar DEPOT, depotkapsler, hårde Madopar Dispersible 125 mg dispergovateľné tablety Madopar HBS 100 mg + 25 mg cápsulas de libertação prolongada Madopar HBS 100 mg/25 mg ilgstošās darbības cietās kapsulas Madopar HBS 100 mg/25 mg pailginto atpalaidavimo kietosios kapsulės Madopar HBS 100 mg/25 mg toimeainet prolongeeritult vabastavad kõvakapslid Madopar HBS 125 mg, capsules met gereguleerde afgifte Madopar HBS 125 mgtvrdé kapsuly s riadeným uvolnovaním Madopar HBS capsule cu eliberare modificată Madopar HBS capsule cu eliberare modificată Madopar HBS tvrdé tobolky s řízeným uvolňováním

not available

7430

F. HOFFMANN-LA ROCHE AG

NO

not available

13087

ROCHE A/S

DK

not available

27/0156/00-S

ROCHE SLOVENSKO S.R.O.

SK

not available

8402933

ROCHE FARMACÊUTICA QUÍMICA, LDA.

PT

not available

96-0353

ROCHE LATVIJA SIA

LV

not available

LT/1/94/0936/004

UAB "ROCHE LIETUVA"

LT

not available

142896

ROCHE EESTI OÜ

EE

not available

RVG 12489

ROCHE NEDERLAND B.V.

NL

not available

27/0168/89-C/S

ROCHE SLOVENSKO S.R.O.

SK

not available

7678/2006/01

ROCHE ROMANIA SRL

RO

not available

7678/2006/02

ROCHE ROMANIA SRL

RO

not available

27/168/89-C

ROCHE S. R. O.

CZ

List of nationally authorised medicinal products EMA/88406/2018

Page 6/12

Product Name (in

MRP/DCP

authorisation country)

Authorisation

National Authorisation Number

MAH of product in the

Member State where

member state

product is authorised

number Madopar HBS, 100 mg + 25 mg, kapsułki Madopar Quick "125" Madopar Quick "62,5" Madopar Quick „62,5“ lausnartöflur Madopar QUICK 100 mg/25 mg lösliga tabletter Madopar Quick„125“ lausnartöflur Madopar RETARD 100/25 mg cápsulas duras de liberación prolongada Madopar Solubile 12,5/50 oppløselige tabletter Madopar, 200 mg + 50 mg, kapsułki Madopar® MADOPAR® 100 mg/25 mg depotkapseli MADOPAR® 100 mg/25 mg tabletti Madopar® 125 mg Hartkapseln Madopar® 125 mg T Tabletten MADOPAR® 200 mg/50 mg tabletti Madopar® 250

not available

R/3775

ROCHE POLSKA SP.O.O.

PL

not available not available not available

18676 18675 970268

ROCHE A/S ROCHE A/S ROCHE A/S

DK DK IS

not available

12242

ROCHE OY

FI

not available

970269

ROCHE A/S

IS

not available

62.162

ROCHE FARMA, S.A.

ES

not available

8052

F. HOFFMANN-LA ROCHE AG

NO

not available

R/0952

ROCHE POLSKA SP.O.O.

PL

not available not available

85847/15/28.12.2016 9882

ROCHE (HELLAS) SA ROCHE OY

GR FI

not available

9672

ROCHE OY

FI

not available

6036937.00.00

ROCHE PHARMA AG

DE

not available

6036937.00.01

ROCHE PHARMA AG

DE

not available

8611

ROCHE OY

FI

not available

52146

ROCHE FARMA S.A.

ES

List of nationally authorised medicinal products EMA/88406/2018

Page 7/12

Product Name (in

MRP/DCP

authorisation country)

Authorisation

National Authorisation Number

MAH of product in the

Member State where

member state

product is authorised

number Madopar® 250 mg Tabletten Levodopa 200 mg Benserazid 50 mg (als Benserazidhydrochlorid) Madopar® 62,5 mg Hartkapseln Levodopa 50 mg Benserazid 12,5 mg (als Benserazidhydrochlorid) Madopar® Depot Hartkapseln, retardiert Levodopa 100 mg Benserazid 25 mg (als Benserazidhydrochlorid) Madopar® LT Tabletten zur Herstellung einer Suspension zum Einnehmen Levodopa 100 mg Benserazid 25 mg (als Benserazidhydrochlorid) MADOPAR® QUICK 100 mg/25 mg liukeneva tabletti Madopark 100 mg/25 mg tabletter Madopark DEPOT 100 mg/25 mg depotkapslar, hårda Madopark Quick 100 mg/25 mg tabletter Madopark Quick mite 50 mg/12,5 mg tabletter

not available

861.00.01

ROCHE PHARMA AG

DE

not available

861.00.00

ROCHE PHARMA AG

DE

not available

17010.00.00

ROCHE PHARMA AG

DE

not available

32582.01.00

ROCHE PHARMA AG

DE

not available

12242

ROCHE OY

FI

not available

10828

ROCHE AB

SE

not available

11479

ROCHE AB

SE

not available

12229

ROCHE AB

SE

not available

10951

ROCHE AB

SE

List of nationally authorised medicinal products EMA/88406/2018

Page 8/12

Product Name (in

MRP/DCP

authorisation country)

Authorisation

National Authorisation Number

MAH of product in the

Member State where

member state

product is authorised

number Maдопар 100 mg/25 mg диспергиращи се таблетки Maдопар 200 mg/50 mg таблетки Modopar 125 (100 mg/25 mg), gélule Modopar 125 (100 mg/25 mg), gélule Modopar 125 (100 mg/25 mg), gélule Modopar 125 (100 mg/25 mg), gélule Modopar 125 (100 mg/25 mg), gélule Modopar 125 (100 mg/25 mg), gélule MODOPAR 125 DISPERSIBLE (100 mg/25 mg), comprimé sécable pour suspension buvable MODOPAR 125 DISPERSIBLE (100 mg/25 mg), comprimé sécable pour suspension buvable Modopar 250 (200 mg/50 mg), gélule Modopar 250 (200 mg/50 mg), gélule Modopar 250 (200 mg/50 mg), gélule Modopar 250 (200 mg/50 mg), gélule

not available

9800255

ROCHE BULGARIA EOOD

BG

not available

20020187

ROCHE BULGARIA EOOD

BG

not available

3400931704355

ROCHE

FR

not available

3400931704126

ROCHE

FR

not available

3400931704294

ROCHE

FR

not available

3400930066553

ROCHE

FR

not available

3400930066560

ROCHE

FR

not available

3400930066577

ROCHE

FR

not available

34009 333 131 2 8

ROCHE

FR

not available

3400930066669

ROCHE

FR

not available

3400931704874

ROCHE

FR

not available

3400931704706

ROCHE

FR

not available

3400931704935

ROCHE

FR

not available

3400930066614

ROCHE

FR

List of nationally authorised medicinal products EMA/88406/2018

Page 9/12

Product Name (in

MRP/DCP

authorisation country)

Authorisation

National Authorisation Number

MAH of product in the

Member State where

member state

product is authorised

number Modopar 250 (200 mg/50 mg), gélule Modopar 250 (200 mg/50 mg), gélule Modopar 62,5 (50 mg/12,5 mg), gélule Modopar 62,5 (50 mg/12,5 mg), gélule Modopar L.P. 125 (100 mg/25 mg), gélule a liberation prolongee Modopar L.P. 125 (100 mg/25 mg), gélule a liberation prolongee Modopar L.P. 125 (100 mg/25 mg), gélule a liberation prolongee MODOPAR L.P. 125 100 mg/25 mg, gélule à libération prolongée MODOPAR L.P. 125 100 mg/25 mg, gélule à libération prolongée MODOPAR L.P. 125 100 mg/25 mg, gélule à libération prolongée Prolopa 125, 100 mg/25 mg, capsules, hard Prolopa 125, 100 mg/25 mg, comprimés dispersibles Prolopa 125, 100 mg/25 mg, comprimés dispersibles

not available

3400930066591

ROCHE

FR

not available

3400930066607

ROCHE

FR

not available

3400932407620

ROCHE

FR

not available

3400930066546

ROCHE

FR

not available

3400930066621

ROCHE

FR

not available

3400930066638

ROCHE

FR

not available

3400930066652

ROCHE

FR

not available

3400932985432

ROCHE

FR

not available

3400932985203

ROCHE

FR

not available

3400932985371

ROCHE

FR

not available

BE054083

N.V. ROCHE S.A.

BE

not available

BE182226

N.V. ROCHE S.A.

BE

not available

0178/04068272

N.V. ROCHE S.A.

LU

List of nationally authorised medicinal products EMA/88406/2018

Page 10/12

Product Name (in

MRP/DCP

authorisation country)

Authorisation

National Authorisation Number

MAH of product in the

Member State where

member state

product is authorised

number Prolopa 125, 100 mg/25 mg, dispergeerbare tabletten Prolopa 125, 100 mg/25 mg, gélules Prolopa 125, 100 mg/25 mg, gélules Prolopa 125, 100 mg/25 mg, Hartkapseln Prolopa 125, 100 mg/25 mg, Hartkapseln Prolopa 125, 100 mg/25 mg, Tabletten zur Herstellung einer Suspension zum Einnehmen Prolopa 125, 100 mg/25 mg, Tabletten zur Herstellung einer Suspension zum Einnehmen Prolopa 250 comprimés Prolopa 250, 200 mg/50 mg, comprimés Prolopa 250, 200 mg/50 mg, tabletten Prolopa 250, 200 mg/50 mg, Tabletten Prolopa 250, 200 mg/50 mg, Tabletten Prolopa HBS 125, 100 mg/25 mg, capsules met verlengde afgifte, hard

not available

BE182226

N.V. ROCHE S.A.

BE

not available

BE054083

N.V. ROCHE S.A.

BE

not available

0178/86070194

N.V. ROCHE S.A.

LU

not available

BE054083

N.V. ROCHE S.A.

BE

not available

0178/86070194

N.V. ROCHE S.A.

LU

not available

BE182226

N.V. ROCHE S.A.

BE

not available

0178/04068272

N.V. ROCHE S.A.

LU

not available not available

0178/04068273 BE132492

N.V. ROCHE S.A. N.V. ROCHE S.A.

LU BE

not available

BE132492

N.V. ROCHE S.A.

BE

not available

BE132492

N.V. ROCHE S.A.

BE

not available

0178/04068273

N.V. ROCHE S.A.

LU

not available

BE149475

N.V. ROCHE S.A.

BE

List of nationally authorised medicinal products EMA/88406/2018

Page 11/12

Product Name (in

MRP/DCP

authorisation country)

Authorisation

National Authorisation Number

MAH of product in the

Member State where

member state

product is authorised

number Prolopa HBS 125, 100 mg/25 mg, gélules à libération prolongée Prolopa HBS 125, 100 mg/25 mg, gélules à libération prolongée Prolopa HBS 125, 100 mg/25 mg, Hartkapseln, retardiert Prolopa HBS 125, 100 mg/25 mg, Hartkapseln, retardiert RESTEX 100 mg/25 mg Retardkapseln RESTEX 100 mg/25 mg Tabletten Restex 100 mg/25 mg Tabletten Restex® 100 mg/25 mg Hartkapseln, retardiert Мадопар HBS 100 mg/25 mg твърди капсули с удължено освобождаване

not available

BE149475

N.V. ROCHE S.A.

BE

not available

0178/04078338

N.V. ROCHE S.A.

LU

not available

BE149475

N.V. ROCHE S.A.

BE

not available

0178/04078338

N.V. ROCHE S.A.

LU

DE/H/0371/002

1-25132

ROCHE AUSTRIA GMBH

AT

DE/H/0371/003

1-25133

ROCHE AUSTRIA GMBH

AT

DE/H/0371/003

44958.00.02

ROCHE PHARMA AG

DE

DE/H/0371/002

44958.00.00

ROCHE PHARMA AG

DE

not available

20030139

ROCHE BULGARIA EOOD

BG

List of nationally authorised medicinal products EMA/88406/2018

Page 12/12

benserazide/levodopa - European Medicines Agency - Europa EU

Feb 8, 2018 - Hartkapseln, retardiert. Levodopa 100 mg. Benserazid 25 mg (als. Benserazidhydrochlorid) not available. 17010.00.00. ROCHE PHARMA AG. DE. Madopar® LT Tabletten zur Herstellung einer. Suspension zum. Einnehmen Levodopa. 100 mg Benserazid 25 mg (als. Benserazidhydrochlorid) not available.

182KB Sizes 0 Downloads 117 Views

Recommend Documents

Agenda - European Medicines Agency - Europa EU
Jul 7, 2017 - COMMUNITY MARKETING AUTHORISATIONS AND EXTENSIONS. 2.1. Opinions ... Quality. Rapp: E. Werner .... solutions table with EMA and CVMP responses to the recommendations made by the FishMed Plus. Coalition ...

May 2016 - European Medicines Agency - Europa EU
Jun 22, 2016 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.

Eleclazine - European Medicines Agency - Europa EU
Feb 9, 2017 - Notification of discontinuation of a paediatric development which is covered by an agreed ... for the following reason(s): (tick all that apply).

July 2017 - European Medicines Agency - Europa EU
Jul 5, 2017 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).

July 2016 - European Medicines Agency - Europa EU
Jul 4, 2016 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).

SME Office - European Medicines Agency - Europa EU
maximises the chances of a successful marketing authorisation. ... marketing authorisation. • inclusion in the public SME ... E-mail [email protected]. Website ...

Agenda - European Medicines Agency - Europa EU
Jun 19, 2017 - and may also vary during the course of the review. ...... ViiV Healthcare UK Limited; Treatment of Human Immunodeficiency Virus ..... adjunctive administration of brivaracetam, Treatment of paediatric patients with partial.

Action plan - European Medicines Agency - Europa EU
5 days ago - Guidelines should include more details on the principles of good information design in which content and layout are ... relevance and importance of the QRD template is also acknowledged in this respect as it is the main tool .... databas

Agenda - European Medicines Agency - Europa EU
Jun 15, 2016 - Agenda - EMA Human Scientific Committees' Working. Parties with Healthcare Professionals' Organisations. (HCPWP) meeting. 15 June 2016, 08:45hrs to 10:30hrs – meeting room: 3E. Chairs: I. Moulon (EMA) and Gonzalo Calvo (HCPWP). 15 Ju

Agenda - European Medicines Agency - Europa EU
Jun 26, 2018 - oxadiazole-3-carboximidamide - EMEA-002072-PIP01-16-M01 . ..... Human alpha-galactosidase A - Orphan - EMEA-001828-PIP01-15-M01 .

Agenda - European Medicines Agency - Europa EU
Jul 16, 2018 - Cladribine, EMA/OD/087/17 Recombinant monoclonal antibody to sialic acid-binding Ig-like lectin 8. 2.2.6. - EMA/OD/098/18. Treatment of ...

SPOR - European Medicines Agency - Europa EU
Feb 7, 2017 - Add an existing Tag to a specific Term . ...... This service creates an email body (text/html) of a user's notification data, a notification is based on.

ATMP - European Medicines Agency - Europa EU
Nov 24, 2017 - E8. 09/08/2017. 10/08/2017. 24/08/2017 17/08/2017 22/08/2017. 24/08/2017. 30/08/2017. 01/09/2017. 04/09/2017. 08/09/2017. 14/09/2017.

Agenda - European Medicines Agency - Europa EU
Feb 9, 2018 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the European Union ... product information. For information: Summary of opinion. 2.2. Oral explanations and list of outstanding issues. •. Product

Agenda - European Medicines Agency - Europa EU
Oct 23, 2017 - Page 2/61. Table of contents. 1. Introduction. 11. 1.1. Welcome and declarations of interest of members, alternates and experts .......... 11. 1.2. Agenda of the meeting on 23-26 October 2017 . ...... different database to study the ri

Evofosfamide - European Medicines Agency - Europa EU
Notification of discontinuation of a paediatric development which is covered by an agreed ... for the following reason(s): (tick all that apply). (possible) lack of ...

Agenda - European Medicines Agency - Europa EU
17 Jan 2018 - Expert meeting on adeno-associated viral vectors, 06 September 2017, EMA, London. CAT: Martina Schüßler-Lenz. Scope: report of the meeting that took place on 6 September 2017. Action: for adoption. 7.6.3. Environmental assessment of g

minoxidil - European Medicines Agency - Europa EU
Jun 14, 2018 - Page 2/26. Product Name (in authorisation country). MRP/DCP Authorisation number. National Authorisation. Number. MAH of product in the.

Influenza vaccine - European Medicines Agency - Europa EU
Oct 26, 2017 - Injektionssuspension in einer Fertigspritze. Influenza-Impfstoff. (Spaltimpfstoff, inaktiviert, in Zellkulturen hergestellt) not available. BE393556. NANOTHERAPEUTICS. BOHUMIL, S.R.O.. BE. Preflucel injektionsvätska, suspension i för

latanoprost - European Medicines Agency - Europa EU
May 13, 2016 - Send a question via our website www.ema.europa.eu/contact. © European ... Product Name (in authorisation ..... Xaloptic Free. NL/H/3193/001.

Cyproterone/ethinylestradiol - European Medicines Agency - Europa EU
March 2016 a joint database drug utilisation final study report to the European .... With regards to prescription of CPA/EE for contraceptive management, ...

ganciclovir - European Medicines Agency - Europa EU
Feb 9, 2017 - Send a question via our website www.ema.europa.eu/contact. © European ... Product Name (in authorisation ... not available. 20010180.

July 2016 - European Medicines Agency - Europa EU
For a list of RSS readers please refer to our RSS guide and follow the instructions ..... PCWP and HCPWP joint meeting: Workshop on social media - Sep 2016.

Stem cell - European Medicines Agency - Europa EU
Jul 14, 2016 - Stem cell-based products for veterinary use: specific ... potentially delay time to rejection providing a window of therapeutic benefit but limiting ...